Recent Updates
Recently added Catalysts

Pemphigus: one US-listed biotech with a clinical-stage programme

Immunology & InflammationUncontestedData as of 2026-09-04

Competitors1in the clinic
Median market cap$590Muniverse median $1.20B
Allocated capital$148M$590M competing
Phase 3 or filed00 mid, 1 early
Pure plays0this indication only
Capital rank268/299crowding rank 269

Pemphigus is uncontested. Cabaletta Bio (CABA) is the only US-listed developer in the $100M to $20B band running a clinical programme here, with CABA-201 in phase 1.

There is no public comparable to price it against. CABA spreads its $590M market cap across 4 indications, so $148M of it is allocated here.

Nothing here has reached Phase 3: 0 programmes in mid stage and 1 in early stage, so the field is still several years from a first approval.

$148M of allocated capital sits in Pemphigus, ranking it 268th of 299 indications by the money committed to it.

Companies developing drugs for Pemphigus 1

TickerCompanyLead assetPhaseTrialsMarket capPure playIndicationsNext catalyst
CABACabaletta BioCABA-201Phase 12$590MNo4 31 Dec 2026

Sorted by phase, then by market capitalisation. Ticker links open the company profile.

Why Pemphigus counts as uncontested

Uncontested. One US-listed developer in the size band is running a clinical programme here, so there is no public comparable to price it against.

The map splits indications on two folds: six or more competitors counts as crowded, and a median company above $1.20B counts as richly priced. Pemphigus has one competitor and a median of $590M.

Immunology & Inflammation

Immunology & Inflammation holds $139B of the map's capital, 20.7% of the total, spread across 51 indications and 82 companies. 23 of those indications have more than one company competing.

See every Immunology & Inflammation indication on the map

Related indications in Immunology & Inflammation

Acute Respiratory Distress Syndrome1 company · $136M · median $272MUncontestedCOPD1 company · $167M · median $333MUncontestedPrevention of Acute Rejection in Renal Transplant1 company · $226M · median $226MUncontestedChildhood-onset Systemic Lupus Erythematosus1 company · $69M · median $276MUncontestedCOPD Exacerbation1 company · $61M · median $122MUncontestedDiffuse Cutaneous Systemic Sclerosis1 company · $51M · median $101MUncontestedOsteoarthritis Patients Scheduled for Total Knee Replacement Surgery1 company · $265M · median $1.1BUncontestedIdiopathic Membranous Nephropathy1 company · $279M · median $838MUncontested

Pemphigus pipeline questions

Which biotech companies are developing drugs for Pemphigus?

Cabaletta Bio (CABA, CABA-201, Phase 1). Those are the 1 US-listed developer in the $100M to $20B market cap band with a clinical-stage programme in Pemphigus.

How advanced is the Pemphigus pipeline?

Of the 1 clinical-stage programme in Pemphigus, 0 are in Phase 3 or filed, 0 are in mid-stage development and 1 is in early-stage development.

Is anyone else developing a drug for Pemphigus?

No. CABA is the only US-listed company in the $100M to $20B market cap band with a clinical-stage programme in Pemphigus, which is why the indication is classified as uncontested.

When is the next Pemphigus catalyst?

The next dated catalyst in Pemphigus is CABA on 31 Dec 2026. 1 dated event across the field fall in the next 12 months.

How this page is built

  • Universe is US-listed drug developers with a $100M to $20B market capitalisation, identified by SEC SIC code 2833, 2834 or 2836 or by a pharmaceutical or biotechnology industry classification, less a reviewed exclusion list of contract research organisations, device and diagnostics makers and diversified generics manufacturers.
  • An asset attributed to three or more different companies is treated as shared standard of care rather than any one company’s programme and excluded. Pembrolizumab alone appears under 21 tickers in raw trial data.
  • A programme counts only where at least one industry-sponsored trial supports it, so investigator-initiated academic studies of third-party drugs are excluded.

Allocated capital divides each company’s market capitalisation evenly across the indications it is running clinical programmes in, so every dollar of the universe is counted exactly once. Total market capitalisation competing counts a company in each of its indications and therefore sums to more than the universe.

Third-party market size estimates are not used anywhere on this page. Approved incumbents are excluded from competitor counts, and companies above $20B are outside the universe by construction.

Back to the disease map